INTRODUCTION
Genetic studies have identifi ed several genetic mutations that are associated with neurodegenerative diseases, including Parkinson ' s disease (PD), Alzheimer ' s disease (AD), amyotrophic lateral sclerosis (ALS), Huntington ' s disease (HD), and Friedrich ' s ataxia (FRDA). It should be noted, however, that familial cases account for only a small percentage of these disorders; most cases of neurodegenerative disease are sporadic. Increasing evidence suggests that mitochondrial dysfunction and oxidative stress play a crucial role in the majority of neurodegenerative diseases. Mitochondria are a major source of intracellular reactive oxygen species (ROS) and are particularly vulnerable to oxidative stress. Oxidative damage to mitochondria has been shown to impair mitochondrial function and lead to cell death via apoptosis and necrosis. Because dysfunctional mitochondria will produce more ROS, a feed-forward loop is set up whereby ROS-mediated oxidative damage to mitochondria favors more ROS generation, resulting in a vicious cycle. It is now appreciated that reduction of mitochondrial oxidative stress may prevent or slow down the progression of these neurodegenerative disorders. This review will summarize the development of a novel class of mitochondriatargeted antioxidants that can protect mitochondria against oxidative stress and prevent neuronal cell death in animal models of stroke, PD, and ALS.
MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE DAMAGE IN NEURODEGENERATIVE DISEASES
A recent review by Beal 1 presented extensive evidence for the involvement of mitochondria in neurodegenerative diseases. Decreased mitochondrial complex I activity has been reported in the substantia nigra of postmortem brain samples from patients with PD, HD, and FRDA. 2 Inhibitors of complex I of the mitochondrial electron transport chain (ETC) produce PD in humans and animals, and knockouts of parkin or DJ-1, which are associated with familial PD, show defective mitochondrial function. 3 , 4 Alzheimer ' s brains harbor somatic mitochondrial DNA (mtDNA) mutations that suppress mitochondrial transcription and replication, 5 and there is evidence that b -amyloid is targeted to mitochondria, where it has been shown to bind ABAD ( b -amyloid binding alcohol dehydrogenase) and to inhibit cytochrome c oxidase. 6 , 7 Mice overexpressing mutant CuZn superoxide dismutase (SOD1), a model for ALS, showed compromised mitochondrial respiration and adenosine triphosphate (ATP) production. 8 , 9 Reduced expression of frataxin in a model of FRDA leads to iron accumulation in mitochondria and impairment of complex I and II of the ETC. 10 Finally, impaired mitochondrial function has been shown in patients with HD, as well as animal models of HD (see review 11 ).
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Mitochondrial dysfunction, whether caused by genetic mutations or environmental factors, leads to increased production of ROS. Evidence that oxidative stress plays a role in PD, AD, and ALS is accumulating. [12] [13] [14] Postmortem analyses have revealed that overall levels of oxidative damage to proteins, lipids, and DNA are elevated in AD and PD brains. 15 Oxidative changes to proteins such as a -synuclein in PD, b -amyloid in AD, and SOD in ALS might result in protein misfolding and aggregate formation. 14 A direct association between ROS production and amyloid plaques has also been demonstrated in transgenic mice and in human AD brain tissue. 16 Several oxidative biomarkers are also elevated in a mouse model of ALS. 17 The brain may be particularly susceptible to oxidative stress because of its high metabolic rate and reduced capacity for cellular regeneration.
MITOCHONDRIAL GENERATION OF ROS
Mitochondria consume nearly 85% to 90% of a cell ' s oxygen to support oxidative phosphorylation by harnessing oxidized fuel to the synthesis of ATP ( Figure 1 ). The energy released by the fl ow of electrons through the ETC is used to pump protons out of the mitochondria inner membrane through complexes I, III, and IV. This creates an electrochemical gradient across the mitochondrial inner membrane. The potential energy stored is coupled to ATP synthesis by complex V (ATP synthase). Oxygen normally serves as the ultimate electron acceptor and is reduced to water. However, electron leak to oxygen through complexes I and III can generate superoxide anion (O 2
• ¯) ( Figure 2 ). 18 The rate of O 2
• ¯ production is affected by mitochondrial metabolic state and increases when the electron carriers harbor excess electrons, either from inhibition of oxidative phosphorylation or from excessive calorie consumption. The location of O 2
• ¯ within mitochondria is important because O 2 • ¯ does not diffuse across membranes. Recent studies suggest that complex I releases O 2
• ¯ into the matrix while complex III can release O 2
• ¯ into the matrix as well as the intermembrane space ( Figure 2 ). 19 • ¯ and can diffuse out of the mitochondrion and into the cytosol ( Figure 3 ). However, in the presence of reduced transitional metals, H 2 O 2 can be converted to the highly reactive hydroxyl radical (OH • ) via the Fenton reaction ( Figure 3 ). OH • may further react with bicarbonate to yield the very reactive carbonate radical anion (CO 3 • ¯). O 2 • ¯ can also react with another free radical, nitric oxide (NO • ), formed by mitochondrial nitric oxide synthase, to generate the highly reactive peroxynitrite (ONOO -) ( Figure 3 ).
FREE RADICAL DAMAGE TO MITOCHONDRIA
Although H 2 O 2 may freely diffuse out of mitochondria, other radicals such as O 2 • ¯ and OH • are largely limited by diffusion and likely to infl ict damage directly to mitochondria, especially to the inner membrane where they are E523 generated. Furthermore, the inner membrane contains many iron and copper complexes, which may catalyze further reactions between O 2
• ¯ and H 2 O 2 . ROS can initiate damage to nucleic acids, proteins, and lipids ( Figure 3 ) . 20 Mitochondrial DNA are more vulnerable than nuclear DNA to oxidative damage because they are situated much closer to the site of ROS generation, and mitochondria lack protective histones and have much more limited base excision repair mechanisms than they do nuclear repair mechanisms. 21 Mitochondrial proteins can be modifi ed by nitration, S-nitrosylation, S-glutathionylation, or carbonylation. Protein oxidation and nitration result in altered function of many metabolic enzymes in the mitochondrial ETC, including nicotinamide adenine dinucleotide (NADH) dehydrogenase, NADH oxidase, cytochrome c oxidase, and ATPase. 20 , 22 Oxidation of the adenine nucleotide translocator (ANT) will impair the infl ux of adenosine diphosphate (ADP) into the matrix for ATP synthesis. Another particularly relevant protein that loses function upon oxidation is MnSOD; its loss of function would further compromise antioxidant capacity and lead to further oxidative stress. 23 ROS, especially OH • , can lead directly to peroxidation of lipids and the production of highly reactive aldehyde species such as 4-hydroxy-2,3,trans-nonenal, which can then result in secondary detrimental effects. 24 Cardiolipin, the major phospholipid on the mitochondria inner membrane, is particularly susceptible to peroxidation because of its high degree of unsaturation. 25 
MITOCHONDRIAL ANTIOXIDANT NETWORK
Mitochondria are normally protected from oxidative damage by a multilayer network of mitochondrial antioxidant systems (see review 26 ). H 2 O 2 can be readily converted to water by mitochondrial glutathione peroxidase, which oxidizes reduced glutathione (GSH) to oxidized glutathione (GSSG). Glutathione reductase then converts GSSG back to GSH. GSH is synthesized in the cytosol and must be imported into mitochondria by a transporter. In addition to GSH, mitochondria have 2 other small thiol-disulfi de oxidoreductases -thioredoxin and glutaredoxin -that play important roles in thiol redox control. Another detoxifi cation enzyme, catalase, is present only in heart mitochondria. In addition to these antioxidant enzymes, mitochondria possess several low-molecular-weight antioxidants, including a -tocopherol and ubiquinol. These molecules are particularly effective in scavenging lipid peroxyl radicals and preventing the free radical chain reaction of lipid peroxidation.
MITOCHONDRIAL OXIDATIVE DAMAGE AND CYTOCHROME C RELEASE
Mitochondria undergo oxidative damage when ROS production exceeds the antioxidant capacity of mitochondria.
One outcome of mitochondrial oxidation is the release of mitochondrial cytochrome c into the cytosol. Cytochrome c is normally bound to the inner mitochondrial membrane by an association with cardiolipin. 27 Peroxidation of cardiolipin leads to dissociation of cytochrome c and its release through the outer mitochondrial membrane. 28 The mechanism by which cytochrome c is released through the outer membrane is not clear. One mechanism may involve mitochondrial permeability transition (MPT). The MPT pore is a high conductance channel that is believed to be formed by the apposition of the voltage-dependent anion channel on the outer membrane and the ANT on the inner membrane. 29 The opening of the MPT pore causes a sudden increase in the permeability of the inner mitochondrial membrane. This results in swelling of the mitochondrial matrix, rupture of the outer membrane, and release of cytochrome c. 30 ROS may promote MPT by causing oxidation of thiol groups on the ANT. 31 Cytochrome c release may also occur via MPTindependent mechanisms and may involve an oligomeric form of Bax. 32 Bax and MPT may also work together to cause cytochrome c release. 33 
MITOCHONDRIAL OXIDATIVE DAMAGE AND CELL DEATH
Cytochrome c released from mitochondria into the cytoplasm binds to Apaf-1 to initiate the formation of an apoptosome, which then binds pro-caspase-9. The oligomerization of caspase-9 on the apoptosome activates the protease. The active caspase-9 cleaves 2 " executioner " caspases, caspase-3 and caspase-7, that then go on to cleave key substrates within the cell. 34 , 35 This has been termed the intrinsic mitochondrial pathway of apoptosis. Depending on the availability of intracellular ATP, the cell death pathway may switch from apoptosis to necrosis ( Figure 4 ). Several enzymes of the ETC have been shown to be inhibited by ROS, and opening of the MPT pore results in mitochondrial depolarization and inhibition of ATP synthesis. In addition, single-strand DNA breaks mediated by ROS activate poly-ADP-ribose polymerase (PARP) for DNA repair. Activated PARP cleaves NAD + into nicotinamide and ADP-ribose, resulting in NAD + and ATP depletion. 36 While apoptosis is the predominant cell death pathway in the presence of adequate ATP, overwhelming depletion of ATP results in necrotic cell death.
ANTIOXIDANTS AS THERAPY FOR NEURODEGENERATIVE DISEASES
There is evidence that some antioxidant treatments can attenuate or delay disease progression in animal models of neurodegenerative diseases. Natural antioxidants ranging from coenzyme Q (CoQ), vitamin E (tocopherol), and creatine to green tea polyphenols have shown protective effects in mice models of PD, ALS, and AD. 37 , 38 However, clinical trials with the same antioxidants have failed to show benefi ts in humans, and high doses of vitamin E may actually be harmful. 39 The diffi culty many antioxidants have with penetrating the blood-brain barrier (BBB) is one possible reason for their lack of effi cacy. It has been reported that feeding rats with CoQ for 2 months failed to increase brain CoQ levels. 40 Furthermore, some antioxidants may not reach the relevant sites of free radical generation ( Figure 5 ). Large proteins like SOD and catalase do not penetrate cell membranes and are therefore ineffective against intracellular ROS. Vitamin E and CoQ are very lipophilic, tend to be retained in cell membranes, and fail to achieve signifi cant intracellular concentrations. To overcome the limitations of natural antioxidants, several low-molecular-weight catalytic antioxidants, generally referred to as SOD mimetics, have been developed (see review 41 ). Several of these SOD mimetics have been reported to be effective in blocking oxidant stress in cell models, including offering protection against cell death induced by 1-methyl-4-phenylpyridium (MPP + ) and paraquat, models of PD. 42 , 43 Two SOD mimetics (EUK-8 and EUK-134) were shown to prolong survival in an ALS model (SOD1 transgenic mice), 44 and systemic administration of EUK-189 reduced striatal dopaminergic cell death caused by paraquat 45 A manganese porphyrin (AEOL 10150) administered to G93A SOD1 mutants (ALS model) at the onset of symptoms prolonged survival by 11%. 46 However, another SOD mimetic, MnTBAP, failed to provide neuroprotection in a SOD1 knockout mouse because it did not cross the BBB. 47 If mitochondria are the major source of intracellular ROS and mitochondria are most vulnerable to oxidative damage, then it would be ideal to deliver the antioxidant therapy to mitochondria. Recently it was shown that overexpression of catalase in mitochondria increased life span by 20% in mice, whereas overexpression of catalase in peroxisomes had no signifi cant effect. 48 Thus, antioxidant effi cacy may be determined by targeted delivery to the site of ROS production.
MITOCHONDRIA-TARGETED ANTIOXIDANTS -MITOCHONDRIAL POTENTIAL-DEPENDENT DELIVERY TPP + -Conjugated Vitamin E and CoQ
The development of mitochondria-targeted antioxidants was recently reviewed by Sheu et al. 49 The most common method for targeting compounds to mitochondria makes use of the potential gradient across the mitochondrial inner membrane. As a result of the proton gradient, a negative potential of 150 to 180 mV is generated across the inner membrane ( Figure 1 ). Lipophilic cations may therefore accumulate 100-to 1000-fold in the mitochondrial matrix. Murphy and coworkers applied this approach by conjugating the triphenylphosphonium cation (TPP + ) to lipophilic antioxidants such as CoQ (MitoQ) and vitamin E (MitoVitE). 50 MitoQ and MitoVitE are both taken up into the mitochondrial matrix in a potential-dependent manner and are effl uxed out of mitochondria upon depolarization. By preferentially accumulating in the mitochondrial matrix, MitoVitE was reported to be 800-fold more potent than idebenone in protecting against GSH depletion in cultured fi broblasts from patients with FRDA, and MitoVitE was 350-fold more potent than trolox (water-soluble vitamin E analog). 51 This enhanced potency of the TPP + -conjugated antioxidants was abolished in cells pretreated with FCCP (carbonyl cyanide 4-(trifl uoromethoxy)phenylhydrazone) to depolarize mitochondria. MitoQ and MitoVitE were also reported to inhibit H 2 O 2 -induced apoptosis in endothelial cells at concentrations of 1 m M. 52 In vivo distribution of the [ 3 H]TPMP (methyltriphenylphosphonium) cation alone was studied in mice after were given in drinking water to mice, detectable levels were found in the liver and the heart after 4 days, although levels in brain tissue remained lower than levels in all other tissues. Isolated hearts taken from rats treated with MitoQ in their drinking water for 14 days were found to be protected ex vivo against ischemia-reperfusion injury. 54 These data suggest that distribution of the TPP + -conjugated antioxidants to the brain is quite restricted and their usefulness for neuroprotection is questionable. These TPP + -conjugated antioxidants have not been evaluated in vivo in animal models of neurodegenerative diseases.
E525 intraperitoneal (IP
The utility of TPP + -conjugated antioxidants may also be limited by their requirement of mitochondrial potential for mitochondrial uptake. All the neurodegenerative diseases are associated with impaired mitochondrial function and are unlikely to have normal mitochondrial potential. Furthermore, the uptake of these antioxidants is self-limiting in that uptake is reduced at concentrations greater than 50 m M. 55 This may be due to the inevitable depolarization of mitochondria when large amounts of cations accumulate in the matrix. In fact, high concentrations of MitoQ have been shown to cause mitochondrial depolarization, 55 , 56 and this may be a problem with chronic use. In addition, MitoQ can undergo autoxidation in mitochondria to generate O 2
• ¯ and causes H 2 O 2 effl ux from mitochondria. Furthermore, MitoQ does not prevent peroxide-induced thiol oxidation and therefore does not prevent MPT pore opening caused by thiol oxidation. 57 
Choline Esters of Glutathione and N-Acetyl-Cysteine
Glutathione (L-g -glutamyl-L-cysteinyl-glycine) plays a very important role in detoxifying ROS and preventing thiol oxidation. Glutathione is synthesized in the cytoplasm and transported into mitochondria via specifi c carriers. Increasing mitochondrial glutathione can be very effective in preventing mitochondrial oxidative stress. N-acetyl-L-cysteine is often used to provide cysteine for glutathione synthesis. Using a similar approach as with the TPP + conjugated antioxidants, Sheu et al prepared choline esters of glutathione and N-acetyl-cysteine (NAC) to enhance the uptake of glutathione and NAC into mitochondria. 49 Early studies have shown that glutathione and NAC can protect against oxidative stress in cultured cells, but in vivo animal studies are not yet available.
MITOCHONDRIA-TARGETED ANTIOXIDANTS -MITOCHONDRIAL POTENTIAL-INDEPENDENT DELIVERY
A novel class of small cell -permeable peptide antioxidants that target mitochondria in a potential-independent manner was reported recently. 58 The structural motif of these SzetoSchiller (SS) peptides centers on alternating aromatic residues and basic amino acids (aromatic-cationic peptides). 58 , 59 The tyrosine (Tyr)-or dimethyltyrosine (Dmt)-containing analogs can scavenge H 2 O 2 , OH • , and ONOO • and inhibit lipid peroxidation in vitro, as demonstrated by the inhibition of linoleic acid oxidation and low-density lipoprotein (LDL) oxidation. Tyrosine can scavenge oxyradicals, forming relatively unreactive tyrosyl radicals, which can be followed by radical-radical coupling to give dityrosine or can react with superoxide to form tyrosine hydroperoxide. 60 Dimethyltyrosine is more effective than tyrosine in scavenging of ROS. The specifi c location of the tyrosine or dimethyltyrosine residue did not seem to be important, as SS-31 (D-Arg-Dmt-Lys-Phe-NH 2 ) was found to be as effective as SS-02 (Dmt-D-Arg-Phe-Lys-NH 2 ) in scavenging H 2 O 2 and inhibiting LDL oxidation. Replacement of tyrosine with phenylalanine (SS-20; Phe-D-Arg-Phe-Lys-NH 2 ) eliminated all scavenging ability. 58 These small peptides contain an amino acid sequence that allows them to freely penetrate cells despite carrying a 3+ net charge at physiologic pH. 61 These aromatic-cationic peptides are taken up into cells in an energy-independent, nonsaturable manner. Uptake studies with [ 3 H]SS-02 and [ 3 H]SS-31 showed rapid cellular uptake, with steady state achieved in less than 30 minutes. 61 , 62 This suggests that these peptides can freely pass through the plasma membrane in both directions. Unlike the larger cationic peptides like Tat peptide, the SS peptides show no evidence of vesicular localization that would result from endocytosis. 63 , 64 These SS peptides have a sequence motif that makes them targeted to mitochondria. Confocal microscopy showed rapid uptake of a fl uorescent analog of SS-02 (SS-19; Dmt-D-Arg-Phe-atnDap-NH 2 ; atn = b -anthraniloyl-L-a , bdiaminopropionic acid) 65 in living cells. 58 The intracellular distribution pattern of the fl uorescent peptide analog was identical to that of Mitotracker TMRM, a fl uorescent dye that is taken up into mitochondria in a potential-driven manner, suggesting that these peptides are targeted to mitochondria. 58 Incubation of isolated mouse liver or brain mitochondria with [ 3 H]SS-02 or [ 3 H]SS-31 confi rmed that these peptides are taken up and concentrated 1000-fold and 10 000-fold, respectively, in mitochondria. 58 , 62 Contrary to the mitochondrial uptake of MitoQ and MitoE, the uptake of these aromatic-cationic peptides into mitochondria is not dependent on mitochondrial potential, as the extent of uptake was reduced by only ~10% to 15% in mitochondria that were depolarized with FCCP. 58 Mitochondria fractionation studies showed that ~85% of the [ 3 H]SS-02 was associated with the inner membrane, further suggesting that these peptides are not targeted to the mitochondrial matrix via potential-dependent mechanisms. Because these positively charged peptides are not delivered into the mitochondrial matrix, their uptake is not self-limiting, and they do not cause mitochondrial depolarization even at 1 mM. 58 
MITOCHONDRIA-TARGETED PEPTIDE ANTIOXIDANTS INHIBIT MITOCHONDRIAL ROS PRODUCTION AND PREVENT MITOCHONDRIAL SWELLING
By targeting the inner membrane, the SS peptides reduce mitochondrial ROS accumulation in a dose-dependent manner. The Dmt-containing peptide analogs, SS-02 and SS-31, inhibited H 2 O 2 release when incubated with isolated mouse liver mitochondria at 37°C ( Figure 6A ). Mitochondrial ROS production can be prevented by mitochondrial depolarization with the use of uncouplers, but none of the SS peptides decreased mitochondrial potential in isolated mitochondria as measured with Mitotracker TMRM ( Figure 6B ). Although it lacks scavenging ability, SS-20 also signifi cantly decreased H 2 O 2 release, but the response was dramatically less compared with the response with the scavenging peptide antioxidants SS-02 and SS-31. Mitochondria ROS generation is known to contribute to mitochondrial swelling caused by high calcium and inorganic phosphate, conditions that mimic ischemia. By reducing mitochondrial ROS production, SS-31 inhibited mitochondrial swelling induced by calcium and P i in a dose-dependent manner and thereby prevented cytochrome c release from mitochondria. 58 Mitochondrial calcium overload is known to stimulate ROS production, and the scavenging peptides may protect mitochondria by scavenging ROS. SS-20, which cannot scavenge H 2 O 2 , was unable to prevent calcium-induced mitochondrial swelling. 58 Furthermore, although trolox can inhibit mitochondrial H 2 O 2 accumulation, it was unable to prevent calcium-induced mitochondrial swelling ( Figure  6C ). This is likely because trolox does not penetrate into mitochondria and can scavenge only extramitochondrial H 2 O 2 . Thus, it appears that targeted delivery of antioxidants to the mitochondrial inner membrane is necessary to protect against Ca 2+ -mediated mitochondrial swelling.
SS PEPTIDES PROTECT MITOCHONDRIA AGAINST OXIDATIVE DAMAGE IN CULTURED CELLS
By targeting and concentrating >1000-fold in the mitochondrial inner membrane, these SS peptides are extremely potent in preventing oxidative cell death. Tert -butylhydroperoxide ( t BHP) is a membrane-permeant prooxidant compound that can induce cell death via apoptosis or necrosis. 66 , 67 t BHP can generate t -butoxyl radicals via the Fenton reaction resulting in lipid peroxidation, depletion of intracellular glutathione, modifi cation of protein thiols, depletion of intracellular ATP stores, and loss of cell viability. Treatment of cells with t BHP causes rapid oxidation of pyridine nucleotides and increased ROS production in mitochondria. 68 , 69 SS-31 was very potent in reducing intracellular ROS and preventing cell death after t BHP treatment, with EC 50 in the nM range. 58 , 62 In contrast, most antioxidants require at least 100 m M to reduce oxidative cell death. 51 , 69 , 70 MitoQ was able to block H 2 O 2 -induced apoptosis at 1 m M, but >10 m M caused cytotoxicity. 56 
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In contrast, no toxicity was observed with 1 mM SS-02 or SS-31.
Recent evidence suggests that t BHP-induced apoptosis is triggered by MPT. 67 The scavenging SS peptides (SS-02 and SS-31) were able to inhibit MPT, prevent mitochondrial swelling, and reduce cytochrome c release in response to Ca 2+ overload. 58 In neuroblastoma N 2 A cells exposed to t BHP, SS-31 prevented mitochondrial depolarization at subnanomolar concentrations and inhibited apoptosis. 62 These results support the proposal that ROS may potentiate MPT via oxidation of the adenine nucleotide translocator. The ability of SS peptides to prevent MPT will minimize MPTinduced ROS accumulation and reduce further oxidative damage on mitochondria.
PHARMACOKINETIC PROPERTIES OF SS PEPTIDES
The SS peptide antioxidants are highly " druggable " and have excellent pharmacokinetic profi les. They are small and easy to synthesize, readily soluble in water, and resistant to peptidase degradation. The presence of a D -amino acid in either the fi rst or the second position minimizes aminopeptidase degradation, and amidation of the C-terminus reduces hydrolysis from the C-terminus. In addition to cellular uptake, transcellular uptake probably occurs: SS-02 was shown to readily penetrate a monolayer of intestinal epithelial cells in both apical-basolateral and basolateral-apical directions. 61 Since these cells possess tight junctions, the results suggest that SS-02 undergoes transcellular uptake. Most important in the consideration of drug development for neuroprotection is whether the drugs can penetrate the BBB. Pharmacokinetic studies have revealed rapid distribution and relatively long elimination half-life for SS-02 in sheep 71 (A. Gifford, unpublished data, 2004) . This ability of SS-02 to penetrate the BBB is confi rmed by the observation that SS-02, which also possess high affi nity for the m opioid receptor, is a very potent analgesic after subcutaneous (SC) administration in mice. 72 The duration of analgesia achieved with a single SC dose of SS-02 is 4 times longer than the duration of analgesia with an equipotent dose of morphine. 65 
SS PEPTIDES PROTECT AGAINST ISCHEMIA-REPERFUSION INJURY EX VIVO AND IN VIVO
Mitochondrial permeability transition and ROS are thought to play a major role in ischemia-reperfusion injury. 73 ROS production during reperfusion is believed to be the triggering event in ischemia-reperfusion injury. Pretreatment with M40403, a small-molecule SOD mimetic, 30 minutes before ligation of the left anterior descending coronary artery signifi cantly reduced oxidative damage to the rat heart, reduced neutrophil infi ltration, and decreased infarct size. 74 Pretreatment of rats with MitoQ in drinking water for 14 days improved cardiac function in the ex vivo heart subjected to acute ischemia-reperfusion, 54 but the effi cacy of MitoQ has not been investigated in vivo. The effi cacy of free radical scavengers in animal studies is often not observed in clinical trials, and this may at least in part be attributed to their administration prior to ischemia in most animal studies, rather than upon reperfusion, as is usually done in patients with acute myocardial infarction. Postischemic administration of a metalloporphyrin catalytic antioxidant (AEOL10113) signifi cantly reduced infarct size in rats subjected to 90-minute occlusion of the middle cerebral artery, but that compound had to be given intracerebroventricularly. 75 Reperfusion of the ex vivo heart after short-term ischemia is associated with progressive decline in cardiac contractile force despite recovery of coronary fl ow and heart rate. This phenomenon, termed myocardial stunning, is also observed in clinical patients and is thought to be mediated by ROS generation during reperfusion. Both SS-02 and SS-31 were able to prevent myocardial stunning when administered upon reperfusion after 30-minute ischemia in the ex vivo guinea pig heart. 58 , 76 In contrast, SS-20, which has no scavenging ability, was unable to prevent myocardial stunning when administered after ischemia. The ability of SS-02 to prevent myocardial stunning has been confi rmed in rats in vivo, 77 and recent studies have shown that pre-ischemic administration of SS-31 IP to rats signifi cantly reduced infarct size. 78 These fi ndings with the SS peptides support the proposal that ROS play a major role in reperfusioninduced myocardial stunning.
SS-31 has also been reported to reduce infarct volume when administered to mice after acute cerebral ischemia. 79 Mice were subjected to 30-minute unilateral occlusion of the middle cerebral artery. SS-31 (2 mg/kg) was administered to mice shortly after onset of reperfusion. Animals treated with SS-31 showed signifi cantly reduced GSH depletion as well as infarct volume and hemispheric swelling compared with saline-treated animals. These data suggest that SS-31 treatment upon reperfusion can minimize ischemic damage by maintaining GSH levels in the ischemic brain. Mutations in CuZn SOD1 have been found in 10% to 20% of ALS patients. Overexpression of G93A SOD1 in mice is a common animal model for ALS. Mutant SOD1 is recruited to spinal cord mitochondria, where it can form aggregates and cause mitochondrial dysfunction. 80 In one study, daily injections of SS-31 (5 mg/kg, SC) to G93A SOD1 mutants before onset of symptoms led to a signifi cant increase in survival and improvement of motor performance. 81 The gain in motor performance was associated with signifi cantly reduced cell loss in the lumbar spinal cord and a reduction in the level of several oxidative markers.
SS PEPTIDES PREVENT NEURONAL CELL LOSS
These studies support the assertion that mitochondrial dysfunction and oxidative damage are major contributors to the pathophysiology of PD and ALS, and that mitochondriatargeted antioxidants such as SS-31 represent a novel therapeutic approach to these and other neurodegenerative disorders.
CONCLUSION
Oxidative damage is believed to be associated with aging and numerous degenerative diseases. However, available antioxidants have not proven to be particularly effective against many of these disorders. A possibility is that some of the antioxidants do not reach the relevant sites of free radical generation, especially if mitochondria are the primary source of ROS generation. The SS antioxidant peptides represent a novel approach, with targeted delivery of antioxidants to the mitochondrial inner membrane, the site of ROS production. By protecting mitochondrial viability, these peptides can also minimize further ROS generation, thus breaking the vicious cycle between mitochondrial dysfunction and ROS ( Figure 7 ) . By selectively concentrating in mitochondria, these peptides are extraordinarily potent in protecting against oxidative cell death. Preclinical studies support their potential use for ischemia-reperfusion injury and neurodegenerative disorders. Although peptides have often been considered poor drug candidates, these small peptides have excellent " druggable " properties, and their ease in crossing the BBB makes them promising agents for the many neurodegenerative diseases for which better treatment strategies are needed. 
